Literature DB >> 18571923

HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients.

Virginia Wolstenholme1, Maria Hawkins, Sue Ashley, Diana Tait, Gillian Ross.   

Abstract

The aim of this retrospective study was to examine the influence of HER2 status on outcome in breast cancer patients following whole brain radiotherapy (WBRT) for cerebral metastases. One hundred and eighty one patients with recordable HER2 status, who received WBRT at single institution were identified and stratified according to HER2 status. Eighty eight were HER2 positive (HER2+) (49%) and 93 HER2 negative (HER2-) (51%). A total of 72 (82%) HER2+ group developed brain metastases whilst on chemotherapy compared with 45 (48%) in HER2- group. Median survival after WBRT was 8 months (1-38) for HER2+ patients and 4 (1-64) for HER2- patients p=0.01. On brain metastasis progression, 18 (20%) of HER2+ patients received further local therapy compared with 6 (6%) in HER2- group. This study shows superior survival in HER2+ group following WBRT as compared to HER2- group and more aggressive management on disease progression in HER2+ group.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18571923     DOI： 10.1016/j.breast.2008.04.006

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


  7 in total

Review 1.  Whole-brain radiation therapy in breast cancer patients with brain metastases.

Authors:  Cyrus Chargari; François Campana; Jean-Yves Pierga; Lionel Védrine; Damien Ricard; Sylvestre Le Moulec; Alain Fourquet; Youlia M Kirova
Journal:  Nat Rev Clin Oncol       Date:  2010-07-13       Impact factor: 66.675

2.  Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer.

Authors:  Shizu Ogawa; Yoshitsugu Horio; Yasusi Yatabe; Takayuki Fukui; Simon Ito; Yoshinori Hasegawa; Tetsuya Mitsudomi; Toyoaki Hida
Journal:  Int J Clin Oncol       Date:  2011-06-30       Impact factor: 3.402

3.  Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study.

Authors:  Emilie Le Rhun; Sophie Taillibert; Fahed Zairi; Patrick Devos; Matthieu Faivre Pierret; François Dubois; Richard Assaker; Etienne Buisset; Jacques Bonneterre; Marie Christine Baranzelli
Journal:  J Neurooncol       Date:  2011-05-06       Impact factor: 4.130

4.  The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation.

Authors:  Shih-Fan Lai; Yu-Hsuan Chen; Tony Hsiang-Kuang Liang; Che-Yu Hsu; Huang-Chun Lien; Yen-Sen Lu; Chiun-Sheng Huang; Sung-Hsin Kuo
Journal:  J Neurooncol       Date:  2018-03-20       Impact factor: 4.130

5.  Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.

Authors:  Y S Yap; G H Cornelio; B C R Devi; C Khorprasert; S B Kim; T Y Kim; S C Lee; Y H Park; J H Sohn; N Sutandyo; D W Y Wong; M Kobayashi; S H Landis; E M Yeoh; H Moon; J Ro
Journal:  Br J Cancer       Date:  2012-08-23       Impact factor: 7.640

6.  Gamma knife radiosurgery for brain metastases from breast cancer.

Authors:  Kyung Il Jo; Young-Hyuck Im; Doo Sik Kong; Ho Jun Seol; Do-Hyun Nam; Jung-Il Lee
Journal:  J Korean Neurosurg Soc       Date:  2013-11-30

7.  Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer.

Authors:  Hidemi Kawajiri; Tsutomu Takashima; Naoki Aomatsu; Shinichiro Kashiwagi; Satoru Noda; Naoyoshi Onoda; Tetsurou Ishikawa; Kosei Hirakawa
Journal:  Oncol Lett       Date:  2014-01-14       Impact factor: 2.967
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.